Payment overview · 2025
General Payments
$102.00
5 reported records · 5 companies
Healthcare provider profile · identity verified
William H Smith, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHATTANOOGA, TN · NPI 1891769212
Verified facts
What the public records show
CMS Open Payments records show William H Smith, MD received $102.00 in general payments during 2025 across 5 reported records.
Boston Scientific Corporation accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $36.31 | 35.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.38 | 18.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.88 | 16.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.76 | 15.4% | 1 | 2025 |
| ALON MEDICAL TECHNOLOGY | Unresolved — no canonical attribution shown | $14.67 | 14.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $102.00 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $36.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 604 | 189 |
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 175 |
| Losartan Potassium | Losartan Potassium | 543 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 398 | 115 |
| Lisinopril | Lisinopril | 387 | 112 |
| Metformin Hcl | Metformin Hcl | 351 | 108 |
| Gabapentin | Gabapentin | 325 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 297 | 97 |
| Omeprazole | Omeprazole | 267 | 76 |
| Furosemide | Furosemide | 264 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 252 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 250 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 244 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 59 |
| Meloxicam | Meloxicam | 191 | 56 |
| Simvastatin | Simvastatin | 185 | 55 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 158 | 128 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 56 |
| Trazodone Hcl | Trazodone Hcl | 142 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 37 |
| Carvedilol | Carvedilol | 134 | 43 |
| Sertraline Hcl | Sertraline Hcl | 130 | 36 |
| Montelukast Sodium | Montelukast Sodium | 126 | 41 |
| Metformin Hcl Er | Metformin Hcl | 123 | 42 |
| Ozempic | Semaglutide | 120 | 27 |
| Azithromycin | Azithromycin | 119 | 88 |
| Pioglitazone Hcl | Pioglitazone Hcl | 115 | 37 |
| Farxiga | Dapagliflozin Propanediol | 113 | 31 |
| Prednisone | Prednisone | 111 | 84 |
| Glipizide | Glipizide | 107 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 41 |
| Potassium Chloride | Potassium Chloride | 93 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 93 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 22 |
| Tramadol Hcl | Tramadol Hcl | 78 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 26 |
| Eliquis | Apixaban | 77 | 27 |
| Lorazepam | Lorazepam | 77 | 19 |
| Allopurinol | Allopurinol | 75 | 23 |
| Atenolol | Atenolol | 75 | 24 |
| Alendronate Sodium | Alendronate Sodium | 73 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 23 |
| Clonazepam | Clonazepam | 71 | suppressed |
| Celecoxib | Celecoxib | 68 | 20 |
| Buspirone Hcl | Buspirone Hcl | 67 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 17 |
| Famotidine | Famotidine | 63 | 23 |
| Baclofen | Baclofen | 61 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 17 |
| Glimepiride | Glimepiride | 60 | 19 |
| Spironolactone | Spironolactone | 60 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 17 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 15 |
| Mirtazapine | Mirtazapine | 54 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 19 |
| Cefdinir | Cefdinir | 51 | 48 |
| Januvia | Sitagliptin Phosphate | 51 | 15 |
| Benazepril Hcl | Benazepril Hcl | 50 | 12 |
| Valsartan | Valsartan | 50 | 21 |
| Finasteride | Finasteride | 48 | 12 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | 17 |
| Alprazolam | Alprazolam | 43 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 40 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Methylprednisolone | Methylprednisolone | 36 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 11 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 13 |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Benzonatate | Benzonatate | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $102.00 · 5 records | Boston Scientific Corporation | AREXVY, BEXSERO, CAPVAXIVE, ENFLONSIA, GARDASIL 9, General - Erectile Dysfunction, M-M-R II, PROQUAD, SHINGRIX, Veozah | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error